Michael Schmidt
Stock Analyst at Guggenheim
(3.82)
# 694
Out of 4,667 analysts
73
Total ratings
56.82%
Success rate
7.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZNTL Zentalis Pharmaceuticals | Maintains: Buy | $12 → $8 | $3.13 | +155.59% | 3 | Nov 15, 2024 | |
| ADAP Adaptimmune Therapeutics | Maintains: Buy | $4 → $3 | $0.66 | +351.33% | 2 | Nov 15, 2024 | |
| EXEL Exelixis | Maintains: Buy | $32 → $33 | $34.65 | -4.76% | 7 | Oct 30, 2024 | |
| IMCR Immunocore Holdings | Downgrades: Neutral | n/a | $32.42 | - | 3 | Oct 7, 2024 | |
| VSTM Verastem | Initiates: Buy | $13 | $3.79 | +243.01% | 1 | Sep 30, 2024 | |
| INCY Incyte | Maintains: Buy | $86 → $92 | $71.05 | +29.49% | 4 | Sep 16, 2024 | |
| NBTX Nanobiotix | Initiates: Buy | $12 | $4.07 | +194.95% | 1 | Aug 28, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Neutral | n/a | $0.57 | - | 2 | May 15, 2024 | |
| IMNM Immunome | Initiates: Buy | $35 | $9.33 | +275.13% | 1 | Apr 15, 2024 | |
| ADCT ADC Therapeutics | Reiterates: Buy | n/a | $1.98 | - | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.04 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 | $2.22 | +215.32% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $345 | $194.26 | +77.60% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.05 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $23.72 | +43.34% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $15.95 | +163.32% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $0.97 | +1,968.04% | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $82 | $94.81 | -13.51% | 1 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 | $8.74 | +71.62% | 3 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $22.69 | - | 1 | Jan 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $20.45 | - | 2 | Jan 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.64 | +846.97% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $8.36 | +258.85% | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.91 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $57.07 | -12.39% | 1 | Mar 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.30 | - | 4 | Mar 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $54.62 | +46.47% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.37 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $3.44 | +59.88% | 2 | Nov 7, 2017 |
Zentalis Pharmaceuticals
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $3.13
Upside: +155.59%
Adaptimmune Therapeutics
Nov 15, 2024
Maintains: Buy
Price Target: $4 → $3
Current: $0.66
Upside: +351.33%
Exelixis
Oct 30, 2024
Maintains: Buy
Price Target: $32 → $33
Current: $34.65
Upside: -4.76%
Immunocore Holdings
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $32.42
Upside: -
Verastem
Sep 30, 2024
Initiates: Buy
Price Target: $13
Current: $3.79
Upside: +243.01%
Incyte
Sep 16, 2024
Maintains: Buy
Price Target: $86 → $92
Current: $71.05
Upside: +29.49%
Nanobiotix
Aug 28, 2024
Initiates: Buy
Price Target: $12
Current: $4.07
Upside: +194.95%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.57
Upside: -
Immunome
Apr 15, 2024
Initiates: Buy
Price Target: $35
Current: $9.33
Upside: +275.13%
ADC Therapeutics
Apr 5, 2024
Reiterates: Buy
Price Target: n/a
Current: $1.98
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.04
Upside: -
Feb 29, 2024
Upgrades: Buy
Price Target: $7
Current: $2.22
Upside: +215.32%
Feb 27, 2024
Maintains: Buy
Price Target: $350 → $345
Current: $194.26
Upside: +77.60%
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.05
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $23.72
Upside: +43.34%
Jul 25, 2023
Maintains: Buy
Price Target: $40 → $42
Current: $15.95
Upside: +163.32%
Jun 27, 2023
Downgrades: Neutral
Price Target: $20
Current: $0.97
Upside: +1,968.04%
May 23, 2023
Maintains: Buy
Price Target: $78 → $82
Current: $94.81
Upside: -13.51%
Mar 21, 2023
Downgrades: Neutral
Price Target: $15
Current: $8.74
Upside: +71.62%
Jan 12, 2023
Downgrades: Neutral
Price Target: n/a
Current: $22.69
Upside: -
Jan 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $20.45
Upside: -
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $2.64
Upside: +846.97%
Jul 19, 2021
Initiates: Buy
Price Target: $30
Current: $8.36
Upside: +258.85%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.91
Upside: -
Mar 9, 2020
Initiates: Buy
Price Target: $50
Current: $57.07
Upside: -12.39%
Mar 5, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.30
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $54.62
Upside: +46.47%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $6.37
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $3.44
Upside: +59.88%